Playing with evolution: In his Nobel lecture, George P. Smith reconstructs the story of the phage‐display idea as he personally experienced it. The development of this technique is a case study in ...how a scientific advance emerges gradually in incremental steps within overlapping global scientific communities.
The success of genome-wide association (GWA) studies for the detection of sequence variation affecting complex traits in human has spurred interest in the use of large-scale high-density single ...nucleotide polymorphism (SNP) genotyping for the identification of quantitative trait loci (QTL) and for marker-assisted selection in model and agricultural species. A cost-effective and efficient approach for the development of a custom genotyping assay interrogating 54,001 SNP loci to support GWA applications in cattle is described. A novel algorithm for achieving a compressed inter-marker interval distribution proved remarkably successful, with median interval of 37 kb and maximum predicted gap of <350 kb. The assay was tested on a panel of 576 animals from 21 cattle breeds and six outgroup species and revealed that from 39,765 to 46,492 SNP are polymorphic within individual breeds (average minor allele frequency (MAF) ranging from 0.24 to 0.27). The assay also identified 79 putative copy number variants in cattle. Utility for GWA was demonstrated by localizing known variation for coat color and the presence/absence of horns to their correct genomic locations. The combination of SNP selection and the novel spacing algorithm allows an efficient approach for the development of high-density genotyping platforms in species having full or even moderate quality draft sequence. Aspects of the approach can be exploited in species which lack an available genome sequence. The BovineSNP50 assay described here is commercially available from Illumina and provides a robust platform for mapping disease genes and QTL in cattle.
The incidence of the neonatal abstinence syndrome, a drug-withdrawal syndrome that most commonly occurs after in utero exposure to opioids, is known to have increased during the past decade. However, ...recent trends in the incidence of the syndrome and changes in demographic characteristics and hospital treatment of these infants have not been well characterized.
Using multiple cross-sectional analyses and a deidentified data set, we analyzed data from infants with the neonatal abstinence syndrome from 2004 through 2013 in 299 neonatal intensive care units (NICUs) across the United States. We evaluated trends in incidence and health care utilization and changes in infant and maternal clinical characteristics.
Among 674,845 infants admitted to NICUs, we identified 10,327 with the neonatal abstinence syndrome. From 2004 through 2013, the rate of NICU admissions for the neonatal abstinence syndrome increased from 7 cases per 1000 admissions to 27 cases per 1000 admissions; the median length of stay increased from 13 days to 19 days (P<0.001 for both trends). The total percentage of NICU days nationwide that were attributed to the neonatal abstinence syndrome increased from 0.6% to 4.0% (P<0.001 for trend), with eight centers reporting that more than 20% of all NICU days were attributed to the care of these infants in 2013. Infants increasingly received pharmacotherapy (74% in 2004-2005 vs. 87% in 2012-2013, P<0.001 for trend), with morphine the most commonly used drug (49% in 2004 vs. 72% in 2013, P<0.001 for trend).
From 2004 through 2013, the neonatal abstinence syndrome was responsible for a substantial and growing portion of resources dedicated to critically ill neonates in NICUs nationwide.
Recent evidence suggests that the duration of protection by bacillus Calmette-Guérin (BCG) may exceed previous estimates with potential implications for estimating clinical and cost-efficacy.
To ...estimate the protection and duration of protection provided by BCG vaccination against tuberculosis, explore how this protection changes with time since vaccination, and examine the reasons behind the variation in protection and the rate of waning of protection.
Electronic databases including MEDLINE, Excerpta Medica Database (EMBASE), Cochrane Databases, NHS Economic Evaluation Database (NHS EED), Database of Abstracts of Reviews of Effects (DARE), Web of Knowledge, Biosciences Information Service (BIOSIS), Latin American and Caribbean Health Sciences Literature (LILACs), MEDCARIB Database, Cumulative Index to Nursing and Allied Health Literature (CINAHL) were searched from inception to May 2009. Index to Theses, System for Information on Grey Literature in Europe (SIGLE), Centre for Agricultural Bioscience International (CABI) Abstracts, Scopus, Article First, Academic Complete, Africa-Wide Information, Google Scholar, Global Health, British National Bibliography for Report Literature, and clinical trial registration websites were searched from inception to October 2009.
Electronic databases searches, screening of identified studies, data extraction and analysis were undertaken. Meta-analysis was used to present numerical and graphical summaries of clinical efficacy and efficacy by time since vaccination. Evidence of heterogeneity was assessed using the tau-squared statistic. Meta-regression allowed the investigation of observed heterogeneity. Factors investigated included BCG strain, latitude, stringency of pre-BCG vaccination tuberculin testing, age at vaccination, site of disease, study design and vulnerability to biases. Rate of waning of protection was estimated using the ratio of the measure of efficacy after 10 years compared with the efficacy in the first 10 years of a study.
Study selection. A total of 21,030 references were identified, providing data on 132 studies after abstract and full-text review. Efficacy. Protection against pulmonary tuberculosis in adults is variable, ranging from substantial protection in the UK MRC trial {rate ratio 0.22 95% confidence interval (CI) 0.16 to 0.31}, to absence of clinically important benefit, as in the large Chingleput trial rate ratio 1.05 (95% CI 0.88 to 1.25) and greater in latitudes further away from the equator. BCG vaccination efficacy was usually high, and varied little by form of disease (with higher protection against meningeal and miliary tuberculosis) or study design when BCG vaccination was given only to infants or to children after strict screening for tuberculin sensitivity. High levels of protection against death were observed from both trials and observational studies. The observed protective effect of BCG vaccination did not differ by the strain of BCG vaccine used in trials.
Reviewed studies showed that BCG vaccination protects against pulmonary and extrapulmonary tuberculosis for up to 10 years. Most studies either did not follow up participants for long enough or had very few cases after 15 years. This should not be taken to indicate an absence of effect: five studies (one trial and four observational studies) provided evidence of measurable protection at least 15 years after vaccination. Efficacy declined with time. The rate of decline was variable, with faster decline in latitudes further from the equator and in situations where BCG vaccination was given to tuberculin-sensitive participants after stringent tuberculin testing.
The main limitation of this review relates to quality of included trials, most of which were conducted before current standards for reporting were formulated. In addition, data were lacking in some areas and the review had to rely on evidence from observational studies.
BCG vaccination protection against tuberculosis varies between populations, to an extent that cannot be attributed to chance alone. Failure to exclude those already sensitised to mycobacteria and study latitude closer to the equator were associated with lower efficacy. These factors explained most of the observed variation. There is good evidence that BCG vaccination protection declines with time and that protection can last for up to 10 years. Data on protection beyond 15 years are limited; however, a small number of trials and observational studies suggest that BCG vaccination may protect for longer. Further studies are required to investigate the duration of protection by BCG vaccination.
The National Institute for Health Research Health Technology Assessment programme.
Hawkmoths (Sphingidae) are conspicuous, large Lepidopterans that play a vital role in terrestrial ecosystems both as pollinators and as ecological indicators of biodiversity. Notwithstanding, there ...has to date been no attempt to assess the conservation status of these species in the Neotropics. This is due in large part to incomplete datasets and a lack of real long-term monitoring data that allows such assessments to be performed applying IUCN criteria. As with most regions in the Neotropics, Sphingid distributional data in Paraguay is limited to presence—absence data, and few species are represented by sufficient museum series to be able to make inferences about their phenology. However, the existing data is sufficient to infer abundance and ecoregion association and does provide a reliable picture of distribution in the country. Given their importance in ecosystem health monitoring, an attempt is made at a preliminary conservation assessment using a simple system encompassing the key criteria for IUCN assessment, but applicable to the data available.
Implications for conservation
The role of insects in ecological systems is often ignored by conservation planners, who base their decisions heavily on vertebrate and habitat-level conservation assessments. However, hawkmoths play key roles in these systems both as pollinators and prey items, and monitoring of their populations can provide important data regards ecosystem health. It is argued that, whilst the methodology proposed here is far from a fool-proof approach, the benefits of attempting a preliminary base-line assessment such as this outweigh the drawbacks of not having more complete data that is unlikely to become imminently available.
Global Carbon Budget 2020 Friedlingstein, Pierre; O'Sullivan, Michael; Jones, Matthew W ...
Earth system science data,
12/2020, Letnik:
12, Številka:
4
Journal Article
Recenzirano
Odprti dostop
Accurate assessment of anthropogenic carbon dioxide (CO2) emissions and
their redistribution among the atmosphere, ocean, and terrestrial biosphere
in a changing climate – the “global carbon budget” ...– is important to
better understand the global carbon cycle, support the development of
climate policies, and project future climate change. Here we describe and
synthesize data sets and methodology to quantify the five major components
of the global carbon budget and their uncertainties. Fossil CO2
emissions (EFOS) are based on energy statistics and cement production
data, while emissions from land-use change (ELUC), mainly
deforestation, are based on land use and land-use change data and
bookkeeping models. Atmospheric CO2 concentration is measured directly
and its growth rate (GATM) is computed from the annual changes in
concentration. The ocean CO2 sink (SOCEAN) and terrestrial
CO2 sink (SLAND) are estimated with global process models
constrained by observations. The resulting carbon budget imbalance
(BIM), the difference between the estimated total emissions and the
estimated changes in the atmosphere, ocean, and terrestrial biosphere, is a
measure of imperfect data and understanding of the contemporary carbon
cycle. All uncertainties are reported as ±1σ. For the last
decade available (2010–2019), EFOS was 9.6 ± 0.5 GtC yr−1 excluding the cement carbonation sink (9.4 ± 0.5 GtC yr−1 when the cement carbonation sink is included), and
ELUC was 1.6 ± 0.7 GtC yr−1. For the same decade, GATM was 5.1 ± 0.02 GtC yr−1 (2.4 ± 0.01 ppm yr−1), SOCEAN 2.5 ± 0.6 GtC yr−1, and SLAND 3.4 ± 0.9 GtC yr−1, with a budget
imbalance BIM of −0.1 GtC yr−1 indicating a near balance between
estimated sources and sinks over the last decade. For the year 2019 alone, the
growth in EFOS was only about 0.1 % with fossil emissions increasing
to 9.9 ± 0.5 GtC yr−1 excluding the cement carbonation sink (9.7 ± 0.5 GtC yr−1 when cement carbonation sink is included), and ELUC was 1.8 ± 0.7 GtC yr−1, for total anthropogenic CO2 emissions of 11.5 ± 0.9 GtC yr−1 (42.2 ± 3.3 GtCO2). Also for 2019, GATM was
5.4 ± 0.2 GtC yr−1 (2.5 ± 0.1 ppm yr−1), SOCEAN
was 2.6 ± 0.6 GtC yr−1, and SLAND was 3.1 ± 1.2 GtC yr−1, with a BIM of 0.3 GtC. The global atmospheric CO2
concentration reached 409.85 ± 0.1 ppm averaged over 2019. Preliminary
data for 2020, accounting for the COVID-19-induced changes in emissions,
suggest a decrease in EFOS relative to 2019 of about −7 % (median
estimate) based on individual estimates from four studies of −6 %, −7 %,
−7 % (−3 % to −11 %), and −13 %. Overall, the mean and trend in the
components of the global carbon budget are consistently estimated over the
period 1959–2019, but discrepancies of up to 1 GtC yr−1 persist for the
representation of semi-decadal variability in CO2 fluxes. Comparison of
estimates from diverse approaches and observations shows (1) no consensus
in the mean and trend in land-use change emissions over the last decade, (2)
a persistent low agreement between the different methods on the magnitude of
the land CO2 flux in the northern extra-tropics, and (3) an apparent
discrepancy between the different methods for the ocean sink outside the
tropics, particularly in the Southern Ocean. This living data update
documents changes in the methods and data sets used in this new global
carbon budget and the progress in understanding of the global carbon cycle
compared with previous publications of this data set (Friedlingstein et al.,
2019; Le Quéré et al., 2018b, a, 2016, 2015b, a, 2014,
2013). The data presented in this work are available at https://doi.org/10.18160/gcp-2020 (Friedlingstein et al., 2020).
This article presents, for the first time, an overview of all known tree species by scientific name and country level distribution, and describes an online database-GlobalTreeSearch-that provides ...access to this information. Based on our comprehensive analysis of published data sources and expert input, the number of tree species currently known to science is 60,065, representing 20% of all angiosperm and gymnosperm plant species. Nearly half of all tree species (45%) are found in just 10 families, with the 3 most tree-rich families being Leguminosae, Rubiaceae, and Myrtaceae. Geographically, Brazil, Colombia, and Indonesia are the countries with the most tree species. The countries with the most country-endemic tree species reflect broader plant diversity trends (Brazil, Australia, China) or islands where isolation has resulted in speciation (Madagascar, Papua New Guinea, Indonesia). Nearly 58% of all tree species are single-country endemics. Our intention is for GlobalTreeSearch to be used as a tool for monitoring and managing tree species diversity, forests, and carbon stocks on a global, regional, and/or national level. It will also be used as the basis of the Global Tree Assessment, which aims to assess the conservation status of all of the world's tree species by 2020.
The Wet Chemistry Laboratory on the Phoenix Mars Lander performed aqueous chemical analyses of martian soil from the polygon-patterned northern plains of the Vastitas Borealis. The solutions ...contained approximately 10 mM of dissolved salts with 0.4 to 0.6% perchlorate (ClO₄) by mass leached from each sample. The remaining anions included small concentrations of chloride, bicarbonate, and possibly sulfate. Cations were dominated by Mg²⁺ and Na⁺, with small contributions from K⁺ and Ca²⁺. A moderately alkaline pH of 7.7 ± 0.5 was measured, consistent with a carbonate-buffered solution. Samples analyzed from the surface and the excavated boundary of the approximately 5-centimeter-deep ice table showed no significant difference in soluble chemistry.
The China Health and Retirement Longitudinal Study (CHARLS) is a nationally representative longitudinal survey of persons in China 45 years of age or older and their spouses, including assessments of ...social, economic, and health circumstances of community-residents. CHARLS examines health and economic adjustments to rapid ageing of the population in China. The national baseline survey for the study was conducted between June 2011 and March 2012 and involved 17 708 respondents. CHARLS respondents are followed every 2 years, using a face-to-face computer-assisted personal interview (CAPI). Physical measurements are made at every 2-year follow-up, and blood sample collection is done once in every two follow-up periods. A pilot survey for CHARLS was conducted in two provinces of China in 2008, on 2685 individuals, who were resurveyed in 2012. To ensure the adoption of best practices and international comparability of results, CHARLS was harmonized with leading international research studies in the Health and Retirement Study (HRS) model. Requests for collaborations should be directed to Dr Yaohui Zhao (yhzhao@nsd.edu.cn). All data in CHARLS are maintained at the National School of Development of Peking University and will be accessible to researchers around the world at the study website. The 2008 pilot data for CHARLS are available at: http://charls.ccer.edu.cn/charls/. National baseline data for the study are expected to be released in January 2013.
Cancer survivorship represents a growing clinical challenge for pain clinicians. The population of cancer survivors is rapidly expanding and many of these patients experience pain as a sequelae of ...their disease and its treatment. The features, pathophysiology and natural history of some painful conditions observed in cancer survivors, such as direct tumour effects, cancer induced bone pain (CIBP) or chronic post-surgical pain have received extensive exposure elsewhere in the literature. In this narrative review, we attempt to ‘fill in the gaps’ in the knowledge, by providing a succinct outline of a range of less well known pain states encountered in the cancer survivor population. These include neuropathies as a result of graft versus host disease (GVHD), novel chemotherapeutic agents and monoclonal antibodies (mAb), and radiation induced pain states. The increasing prevalence of visceral post-surgical pain and aromatase inhibitor-induced arthralgia (AIA) is also detailed. Additionally an overview of suggested approaches to the assessment of pain in cancer survivors is provided and potential treatment strategies, with a focus on novel approaches are discussed.
PDF
